Thomson Reuters brings together unsurpassed research expertise, innovation, and comprehensive observational data to advance the quality and relevance of comparative effectiveness research (CER) in the U.S. healthcare system.

Research Expertise
We have been conducting CER using the Thomson Reuters MarketScan® Research Databases and other data sources for nearly two decades. With a large and experienced staff of researchers, we work with academic, government, payer, and biopharmaceutical clients on a variety of healthcare projects including those related to CER. Our researchers have a reputation for analytical work that meets the highest academic and professional standards with studies that are well published in peer-reviewed journals.

Innovation in Research
In addition to analytic expertise, Thomson Reuters has a long-standing reputation for excellence in data integration and analytic tool development for healthcare decision-making. This expertise is being brought to bear in exciting new partnership projects designed to enhance data sets, develop clinical guidelines, and make comprehensive data more readily available for CER.

Comprehensive Data for Research
As CER studies search for evidence of treatment response heterogeneity, researchers turn to large, retrospective databases such as the MarketScan Research Databases. Claims data allow investigators to efficiently examine large patient subgroups over extended periods of time. Observational studies using claims can supplement results reported from clinical trials by reporting outcomes from real-world clinical practice.  Clinical richness is continually added to our databases, enabling comparative research on increasingly detailed outcomes.